Last reviewed · How we verify
Etonogestrel implant
Etonogestrel implant, marketed by Oregon Health and Science University, is a long-acting contraceptive with a key composition patent expiring in 2028. Its primary strength lies in its long-term efficacy and ease of use, positioning it as a reliable option in the contraceptive market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Etonogestrel implant |
|---|---|
| Also known as | Nexplanon, Implanon, Implanon, Etonogestrel implant, Implanon NXT |
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) (PHASE3)
- Long Term Evaluation of Scapular-inserted Contraceptive Implants (PHASE2)
- Vapocoolant Spray to Reduce Pain With Nexplanon Insertion (NA)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Breastfeeding Etonogestrel Implant Study (PHASE4)
- Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study (PHASE2)
- Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel (EARLY_PHASE1)
- Effects of the Contraceptive Implant in Women With Sickle Cell Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etonogestrel implant CI brief — competitive landscape report
- Etonogestrel implant updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI